Beneficial effects of a standardised saffron extract (SafrInside™) on premenstrual syndrome: a multicentric, double-blind, randomized, placebo-controlled trial
- 1Activ'Inside, 33750 Beychac et Caillau, France
Abstract
BackgroundPremenstrual syndrome (PMS) affects nearly half of women of reproductive age and can substantially impair quality of life, daily functioning, and psychological well-being. Although saffron extract has been proposed as a potential non-pharmacological approach for PMS management, clinical evidence remains limited. This randomized, multicentric, double-blind, placebo-controlled trial evaluated the efficacy and tolerability of saffron extract in reducing PMS symptoms.
MethodsA total of 110 healthy women aged 18-45 years with mild-to-moderate PMS were randomized to receive saffron extract (30 mg/day; SafrInsideTM) or placebo for three menstrual cycles. The primary endpoint was the Premenstrual Assessment Form-Short Form (PAF-SF) total score. Secondary endpoints included PAF-SF affect, pain, and water retention subscales, and the Patient Health Questionnaire-4 (PHQ-4) total score. Efficacy analyses were performed in the intention-to-treat (ITT) and per-protocol populations using linear mixed-effects models.
ResultsSaffron supplementation resulted in a significantly greater reduction in overall PMS symptoms than the placebo (difference in slope for PAF-SF total score: -1.88; 95% confidence interval [CI] -2.64 to -1.12; p<0.001). Between-group differences in change from baseline were significant at 7 days (-2.42; 95% CI -4.79 to -0.04; p=0.046), 35 days (-3.40; 95% CI -5.78 to -1.02; p=0.010), and 63 days of supplementation (-5.96; 95% CI -8.34 to -3.58; p<0.001). Significant improvements were also observed for affective symptoms (p=0.003), pain (p<0.001), water retention (p<0.001) from the PAF-SF, and psychological distress as assessed by the PHQ-4 total score (p=0.011). No adverse events were reported.
ConclusionsDaily supplementation with saffron extract over three menstrual cycles significantly improved overall PMS symptom severity compared with placebo in women with mild-to-moderate PMS. Benefits were also observed for affective, pain, and water retention symptoms. Saffron extract was well-tolerated and may represent a promising non-pharmacological option for women experiencing bothersome PMS symptoms.
Trial registrationNCT07013539, date of registration 02/06/2025
Related
- A Kampo medicine, kamishoyosan, ameliorates menstruation-associated symptoms in patients with premenstrual syndrome: An exploratory open-label, randomized controlled trial
- Immunogenicity and safety of an interchangeable vaccination schedule of two inactivated Japanese encephalitis vaccines: a multicentric, phase IV, open-label, randomized controlled trial
- Efficacy and safety of Siddha regimen for management of mild to moderate iron deficiency anaemia amongst reproductive age-group women as compared to iron folic acid supplements: A protocol for an open labelled, multicentric randomized equivalence trial.
- Evaluation of the Efficacy and Safety of Ashwagandha Caplet in Patients Suffering from Mild to Moderate Stress and Anxiety Disorders: A Multicentric, Double-Blind, Randomized, Placebo-Controlled, Clinical Trial.
- Effectiveness and safety of a New Standardised TrEatment Protocol based on initial/early therapy with single-pill combinations of blood pressure-lowering drugs for improving blood pressure control (NewSTeP): Rationale, design of a randomized clinical trial and baseline characteristics of the trial participants
BibTeX
@misc{pouchieu2026beneficial,
title = {{Beneficial effects of a standardised saffron extract (SafrInside™) on premenstrual syndrome: a multicentric, double-blind, randomized, placebo-controlled trial}},
author = {C. Pouchieu and R. Villa and F. Amone and L. Pourtau and B. Moras and V. Nobile},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.19.26365879},
url = {https://www.medrxiv.org/content/10.64898/2026.10.19.26365879v1},
note = {CC BY-ND},
}
RIS
TY - UNPB
TI - Beneficial effects of a standardised saffron extract (SafrInside™) on premenstrual syndrome: a multicentric, double-blind, randomized, placebo-controlled trial
AU - C. Pouchieu
AU - R. Villa
AU - F. Amone
AU - L. Pourtau
AU - B. Moras
AU - V. Nobile
PY - 2026
DA - 2026/10/19
PB - medRxiv
DO - 10.64898/2026.10.19.26365879
UR - https://www.medrxiv.org/content/10.64898/2026.10.19.26365879v1
AB - BackgroundPremenstrual syndrome (PMS) affects nearly half of women of reproductive age and can substantially impair quality of life, daily functioning, and psychological well-being. Although saffron extract has been proposed as a potential non-pharmacological approach for PMS management, clinical evidence remains limited. This randomized, multicentric, double-blind, placebo-controlled trial evaluated the efficacy and tolerability of saffron extract in reducing PMS symptoms. MethodsA total of 110 healthy women aged 18-45 years with mild-to-moderate PMS were randomized to receive saffron extract (30 mg/day; SafrInsideTM) or placebo for three menstrual cycles. The primary endpoint was the Premenstrual Assessment Form-Short Form (PAF-SF) total score. Secondary endpoints included PAF-SF affect, pain, and water retention subscales, and the Patient Health Questionnaire-4 (PHQ-4) total score. Efficacy analyses were performed in the intention-to-treat (ITT) and per-protocol populations using linear mixed-effects models. ResultsSaffron supplementation resulted in a significantly greater reduction in overall PMS symptoms than the placebo (difference in slope for PAF-SF total score: -1.88; 95% confidence interval [CI] -2.64 to -1.12; p<0.001). Between-group differences in change from baseline were significant at 7 days (-2.42; 95% CI -4.79 to -0.04; p=0.046), 35 days (-3.40; 95% CI -5.78 to -1.02; p=0.010), and 63 days of supplementation (-5.96; 95% CI -8.34 to -3.58; p<0.001). Significant improvements were also observed for affective symptoms (p=0.003), pain (p<0.001), water retention (p<0.001) from the PAF-SF, and psychological distress as assessed by the PHQ-4 total score (p=0.011). No adverse events were reported. ConclusionsDaily supplementation with saffron extract over three menstrual cycles significantly improved overall PMS symptom severity compared with placebo in women with mild-to-moderate PMS. Benefits were also observed for affective, pain, and water retention symptoms. Saffron extract was well-tolerated and may represent a promising non-pharmacological option for women experiencing bothersome PMS symptoms. Trial registrationNCT07013539, date of registration 02/06/2025
ER -